Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJAN Filings
Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has notified the company that it will not meet the Prescription Drug User Fee Act (PDUFA) goal dates for the New…
Read More...
Read More...
